Chemistry:SER150
From HandWiki
SER150 (formerly EV 077) is an inhibitor of thromboxane synthase and an antagonist of the thromboxane prostanoid receptor. It was developed for diabetic nephropathy.[1][2][3]
References
- ↑ Kim, Yoon Kook; Ning, Xinyuan; Munir, Kashif M.; Davis, Stephen N. (2 October 2022). "Emerging drugs for the treatment of diabetic nephropathy". Expert Opinion on Emerging Drugs 27 (4): 417–430. doi:10.1080/14728214.2022.2155632.
- ↑ McFarlane, Samy I. (2020) (in en). Kidney Disease in Diabetes. Bentham Science Publishers. p. 101. ISBN 978-981-14-2199-0. https://books.google.com/books?hl=en&lr=&id=fHLcDwAAQBAJ&oi=fnd&pg=PA90&dq=SER150+thromboxane&ots=HbV-ZAChka&sig=qEIx3bYCm9IKokC94RycC15igL0#v=onepage&q=SER150%20thromboxane&f=false.
- ↑ Tan, Seng Kiong; Cooper, Mark E. (28 October 2023). "Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?". Expert Opinion on Emerging Drugs: 1–10. doi:10.1080/14728214.2023.2277762.
![]() | Original source: https://en.wikipedia.org/wiki/SER150.
Read more |